TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01342198
Drug: erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
Study: NCT00615212
Drug: GSK376501
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
Study: NCT03808142
Drug: Betaferon, BAY86-5046
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT01725126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as powder and Capsule.
Study: NCT01128270
Drug: Dichloroacetate environmental dose
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
Study: NCT01128270
Drug: Chloral Hydrate environmental dose
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
Study: NCT02224703
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224703
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03129126
Drug: LP-10
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical tacrolimus
Study: NCT02859129
Drug: rosuvastatin 40 mg tablet
Normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
Study: NCT02859129
Drug: Epanova™ QD (2 x 1 g capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
Study: NCT02859129
Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
Study: NCT02859129
Drug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
Study: NCT00615212
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
Study: NCT00002477
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002477
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04277884
Drug: Firibastat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration 2×250 mg capsules bid
Study: NCT04277884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration 2 capsules bid
Study: NCT01093469
Drug: EpiCeram
Normalized name: EPICERAM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03635099
Drug: Placebo (fasted)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study: NCT03635099
Drug: BI 25 mg (fasted)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study: NCT03635099
Drug: BI 50 mg (fasted)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study: NCT03635099
Drug: BI 100 mg (fasted)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study: NCT03635099
Drug: BI 200 mg (fasted)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Study: NCT03635099
Drug: Placebo (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
Study: NCT03635099
Drug: BI 200 mg twice daily, 400 mg total (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Study: NCT01647308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Study: NCT02888574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT00047697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo used in placed of Donepezil HCL
Study: NCT00468143
Drug: Adderall ® Immediate Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
Study: NCT01582230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
Study: NCT02297490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
Study: NCT01229605
Drug: Cyclophosphamide and docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
Study: NCT01162863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken orally for 28 days
Study: NCT01297530
Drug: BAY87-2243
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT02855164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT00089466
Drug: AMD11070
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD11070 taken daily. Dosage dependent on arm.
Study: NCT00709267
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00924742
Drug: Tapimycin (piperacillin 4 g + tazobactam 0.5g)
Normalized name: erythromycin stearate Oral Suspension [Arpimycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
Study: NCT00483990
Drug: PSD502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01097213
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
Study: NCT01681121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
Study: NCT03446612
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Study: NCT01281839
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Study: NCT02273258
Drug: SAR342434
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT01310231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT04224402
Drug: mFOLFORINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT00630734
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg by mouth daily on days 1-4
Study: NCT00630734
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg by mouth daily on days 15-18
Study: NCT01815853
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
Study: NCT03916640
Drug: ADO09 formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of ADO09 formulation
Study: NCT03916640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 0.9% NaCl
Study: NCT03916640
Drug: Symlin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of pramlintide
Study: NCT03916640
Drug: Humulin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of human insulin
Study: NCT03916640
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of insulin lispro
Study: NCT04977791
Drug: Anti-PD-1/PD-L1 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observe a situation before and after immunotherapy
Study: NCT00427570
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03446612
Drug: L-N-monomethyl arginine acetate (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
Study: NCT02156323
Drug: RO7033877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of RO7033877 over 2.5 days
Study: NCT02156323
Drug: RO7033877 + CMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of RO7033877 and CMS over 2.5 days
Study: NCT01214642
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT00380302
Drug: AVE1625
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01201577
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250mg od
Study: NCT02165813
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
Study: NCT00032175
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02535975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets placebo PO three times a day for 24 weeks
Study: NCT04307940
Drug: Naproxen Sodium (Aleve, BAY117031)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 220 mg per tablet, two tablets (440 mg), intake a single dose orally.
Study: NCT04307940
Drug: Hydrocodone/Acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
Study: NCT04307940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets, intake a single dose orally.
Study: NCT03435601
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Study: NCT04227184
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet containing no active drug
Study: NCT01969682
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Study: NCT02959112
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01037556
Drug: PR104
Normalized name: PR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
Study: NCT00127205
Drug: ibandronate sodium
Normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00127205
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00474721
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02181972
Drug: Gingko biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03845140
Drug: L-PZQ ODT 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
Study: NCT03845140
Drug: Biltricide®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.
Study: NCT03845140
Drug: L-PZQ ODT 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
Study: NCT04291053
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment + Huaier Granule 20g po tid for 2weeks
Study: NCT02088957
Drug: Phenytoin intravenous solution
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use
Study: NCT02088957
Drug: Phenytoin oral tablets
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use
Study: NCT00655330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01736358
Drug: Intranasal Ketoralac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery
Study: NCT01736358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
Study: NCT01340911
Drug: SRT3025
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
Study: NCT01340911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
Study: NCT00050089
Drug: Standard ART vs Mega ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy vs Intensified therapy
Study: NCT00443924
Drug: INS115644 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
Study: NCT00443924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of placebo in each eye every 12 hours for three days
Study: NCT00443924
Drug: INS115644 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study: NCT00443924
Drug: INS115644 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study: NCT00443924
Drug: INS115644 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study: NCT02574845
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01093677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution placebo BID for 14 days.
Study: NCT04039503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC as add-on to the pre-trial background medication.
Study: NCT03596762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00643292
Drug: azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin SR 60 mg/kg x 1 dose
Study: NCT02377713
Drug: KHK6640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administration
Study: NCT02377713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administration
Study: NCT02089568
Drug: Co-Amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive 1.2g co-amoxiclav at induction
Study: NCT02089568
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 0.9% saline
Study: NCT00227942
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00214019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo diskus
Study: NCT04515290
Drug: TSG-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
Study: NCT04515290
Drug: TSG-01 and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
Study: NCT04515290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
Study: NCT00669877
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
Study: NCT00669877
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study: NCT01706211
Drug: BRL 49653C
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
Study: NCT01706211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01352234
Drug: Acetylsalicylic Acid 160 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule containing Acetylsalicylic Acid 160mg pill with lactose
Study: NCT01352234
Drug: Acetylsalicylic Acid 80 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Study: NCT00669877
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
Study: NCT01492153
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator